The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
03 Oct 2024
Historique:
received: 07 08 2024
accepted: 23 09 2024
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 3 10 2024
Statut: aheadofprint

Résumé

Cough severity represents an important endpoint to assess the impact of therapies for patients with refractory chronic cough (RCC). To develop a new patient-reported outcome measure addressing cough severity in patients with RCC. Phase 1 (item generation): A systematic survey, focus groups, and expert consultation generated 51 items. Phase 2 (item reduction): From a list of 51 items, 100 patients identified those they had experienced in the previous year and rated their importance on a 5-point scale. The MCSQ included items reported to occur most frequently and that had the highest importance scores. Patient feedback on the MCSQ led to elimination of redundant items. Another 100 patients completed the MCSQ, from which we performed an exploratory factor analysis and a Rasch analysis to further refine items on the MCSQ. Phase 2 led to selection of 15 items from the initial 51. Patient feedback on the 15 items led to elimination of 5 redundant items. An exploratory factor analysis of the 10-item MCSQ led to selection of two domains, elimination of one item that demonstrated cross-loading, and another that had high inter-item correlations. A Rasch analysis of the 8-item MCSQ confirmed that the response options functioned in a logically progressive manner and that no items exhibited differential item functioning. The final 8-item MCSQ has a one-week recall period and includes two domains (intensity and frequency). The 8-item MCSQ had high internal consistency (Cronbach's alpha, 0.89), proved able to distinguish different levels of cough severity (Pearson separation index, 0.89), and demonstrated high cross-sectional convergent validity (Pearson's correlation, 0.76 [95% CI 0.66 to 0.83]) with the 100-mm cough severity visual analogue scale. Initial evidence supports the validity of the MCSQ, an 8-item instrument measuring cough severity in patients with RCC. Future studies should evaluate its properties in measuring change over time.

Sections du résumé

BACKGROUND BACKGROUND
Cough severity represents an important endpoint to assess the impact of therapies for patients with refractory chronic cough (RCC).
OBJECTIVE OBJECTIVE
To develop a new patient-reported outcome measure addressing cough severity in patients with RCC.
METHODS METHODS
Phase 1 (item generation): A systematic survey, focus groups, and expert consultation generated 51 items. Phase 2 (item reduction): From a list of 51 items, 100 patients identified those they had experienced in the previous year and rated their importance on a 5-point scale. The MCSQ included items reported to occur most frequently and that had the highest importance scores. Patient feedback on the MCSQ led to elimination of redundant items. Another 100 patients completed the MCSQ, from which we performed an exploratory factor analysis and a Rasch analysis to further refine items on the MCSQ.
RESULTS RESULTS
Phase 2 led to selection of 15 items from the initial 51. Patient feedback on the 15 items led to elimination of 5 redundant items. An exploratory factor analysis of the 10-item MCSQ led to selection of two domains, elimination of one item that demonstrated cross-loading, and another that had high inter-item correlations. A Rasch analysis of the 8-item MCSQ confirmed that the response options functioned in a logically progressive manner and that no items exhibited differential item functioning. The final 8-item MCSQ has a one-week recall period and includes two domains (intensity and frequency). The 8-item MCSQ had high internal consistency (Cronbach's alpha, 0.89), proved able to distinguish different levels of cough severity (Pearson separation index, 0.89), and demonstrated high cross-sectional convergent validity (Pearson's correlation, 0.76 [95% CI 0.66 to 0.83]) with the 100-mm cough severity visual analogue scale.
CONCLUSION CONCLUSIONS
Initial evidence supports the validity of the MCSQ, an 8-item instrument measuring cough severity in patients with RCC. Future studies should evaluate its properties in measuring change over time.

Identifiants

pubmed: 39362666
pii: 13993003.01565-2024
doi: 10.1183/13993003.01565-2024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.

Auteurs

Elena Kum (E)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Gordon H Guyatt (GH)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Rayid Abdulqawi (R)

King Faisal Specialist Hospital and Research Centre and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Peter Dicpinigaitis (P)

Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.

Lieven Dupont (L)

Department of Respiratory Diseases, University Hospital Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.

Stephen K Field (SK)

Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Cynthia L French (CL)

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, UMass Memorial Medical Center, Worcester, MA, USA.

Peter G Gibson (PG)

Priority Research Centre for Asthma and Respiratory Diseases and Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia.

Richard S Irwin (RS)

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, UMass Memorial Medical Center, Worcester, MA, USA.

Faye Johnston (F)

Chronic Cough Canada, Canada.

Lorcan McGarvey (L)

Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.

Robert Newman (R)

Chronic Cough Canada, Canada.

Nada Popovic (N)

Chronic Cough Canada, Canada.

Jaclyn A Smith (JA)

Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.

Woo-Jung Song (WJ)

Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Paul M O'Byrne (PM)

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ontario, Canada.

Imran Satia (I)

Department of Medicine, McMaster University, Hamilton, Ontario, Canada satiai@mcmaster.ca.
Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ontario, Canada.

Classifications MeSH